Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-3037MO in dyslipidemia
NCT02532218Phase 2Unknown
- Sponsor
- Arisaph Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARI-3037MO in dyslipidemia, sponsored by Arisaph Pharmaceuticals. Status: unknown.
02
Drugs
ARI-3037MO
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02532218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532218.